Aventis Pharma Deutschland, Gmbh

Nicholas Piramal India Limited

Ravi Gajanan Bhat

Joachim Wink

Gerhard Seibert

Jozsef Aszodi

Michael Kurz

Cordula Hopmann

Dominique Le Beller

Triptikumar Mukhopadhyay

Nirogi Venkata Satya Ramakrishna

Rajendra Prakash Tanpure

Uttara Vinayak Oak

Shantilal Dayaram Naker

Erra Koteswara Satya Vijayakumar

Eyyammadichiyil Sankaranarayanan Sreekumar

E S Sreekumar

The present invention relates to novel crystalline glucosamine sulphate metal salts for use in the treatment of acute and chronic forms of rheumatic and arthritic diseases and of all the pathological conditions originating from metabolic disorders of the osteo-articular tissues. More particularly, the present invention relates to novel crystalline glucosamine sulphate metal salts having low metal content wherein the metal may be either sodium or potassium. The present invention further relates to a solution-based and a solvent-free process for the preparation of the novel crystalline glucosamine sulphate metal salts having low metal content and to pharmaceutical compositions comprising the novel crystalline glucosamine sulphate metal salts having low metal content.

Crystalline glucosamine sulfate metal salts and processes for preparing the same

The present invention relates to a compound named Vancoresmycin which is obtainable by cultivation of the microorganism HIL-006734 (DSM 12216), and to its pharmaceutically acceptable salts. The present invention further relates to a process for the production of Vancoresmycin, to the microorganism HIL-006734 (DSM 12216), to the use of Vancoresmycin and its pharmaceutically acceptable salts as pharmaceuticals, and in particular to their use as antibiotics, and to pharmaceutical compositions comprising Vancoresmycin or a pharmaceutically acceptable salt thereof.

Vancoresmycin, a process for its production and its use as a pharmaceutical

Growing community of inventors

Mumbai, India

Ravi Gajanan Bhat